CTLA-4 gene polymorphisms (-318C/T, +49A/G, +6230A/G) in Iranian patients with multiple sclerosis

Iranian Journal of Allergy, Asthma and Immunology

Volumn 9, Issue 4, 2010, Pages 219-223

  Heidari, Abolfazl ^a   Keramatipour, Mohammad ^a   Amirzargar, Ali Akbar ^b   Rashidi Nezhad, Ali ^a   Sahmani, Ahmad Ali ^c   Mozhdehipanah, Hossein ^c   Daloii, Mohammad Reza Noori ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CTLA 4; Multiple sclerosis; RFLP; Single nucleotide polymorphism

Indexed keywords

ADENOSINE; CYTOSINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GUANINE; THYMINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650849913     PISSN: 17351502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sawcer S, Compston A. The genetics analysis of multiple sclerosis in Europeans: concepts and designs. J Neuroimmunol 2003; 143:13-16.
2. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000; 165:1352-6.
3. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105:13-21.
4. Dariavach P, Mattei M, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence murine and human CTLA-4 cytoplasmic domains. Eur. J. Immunol 1998; 18(12):1901-5.
5. Kristiansen O, Larsen Z, Pociot F. CTlA-4 in autoimmune diseases-A general susceptibility gene to autoimmunity? Genes Immun 2000; 1(3):170-84.
6. Walsh EC, Guschwan-McMahon S, Daly MJ, Hafler DA, Rioux JD. Genetic analysis of Multiple Sclerosis. J. Autoimmun 2003; 21:111-6.
7. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature 2003; 423(6939):506-11.
8. Wasay M, Khatri IA, Khealani B, Sheerani M. MS in Asian countries. Int MS J 2006; 13(2):58-65.
9. Vaidya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur J Endocrinal 2004; 150(5):619-26.
10. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis Fa, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13(3):227-31.
11. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, et al. CTLA-4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab 1997; 82(1):143-6.
12. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991; 38(1):1-15.
13. Amirzargar A, Mytilineos J, Yousefipour A, Farjadian S, Scherer S, Opelz G, et al. HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis patients. Eur J Immunogenet 1998; 25(4):297-301.
14. Amirzargar AA, Tabasi A, Khosravi F, Kheradvar A, Rezaei N, Naroueynejad M, et al. Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4-year follow-up study. Eur J Neurol 2005; 12(1):25-30.
15. Torres B, Aguilar F, Franco E, Sánchez E, Sánchez- Román J, Jiménez Alonso J, et al. Association of the CT60 marker of the CTLA-4 gene with systemic lupus erythematosus. Arthritis Rheum 2004; 50(7):2211-5.
16. Andreevskiǐ TV, Sudomoina MA, Gusev EI, Boǐko AN, Alekseenkov AD, Favorova OO. Polymorphism A/G in Position +49 of CTLA4 Exon 1 in Multiple Sclerosis in Russians. Molecular Biology 2004; 36(4): 505-509.
17. Greve B, Simonenko R, Illes Z, Peterfalvi A, Hamdi N, Mycko MP, et al. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Multiple Sclerosis 2008; 14(2):153-8.
18. Wray BN, Stankovich J, Whittock L, Dwyer T, Ponsonby AL, van der Mei IA, et al. CTLA-4 and multiple sclerosis: The A49G single nucleotide polymorphism shows no association with multiple sclerosis in a Southern Australian population. Journal of Neuroimmunology 2008; 196(1-2):139-42.
19. Masterman T, Ligers A, Zhang Z, Hellgren D, Salter H, Anvret M, et al. CTLA4 dimorphisms and the multiple sclerosis phenotype. Journal of Neuroimmunology 2002; 131(1-2):208-12.
20. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O. The CTLA-4 gene is associated with multiple sclerosis. J Neuroimmunol 1999; 97:182-90.
21. Masterman T, Ligers A, Zhang Z, Hellgren D, Salter H, Anvret M, et al. CTLA4 dimorphisms and the multiple sclerosis phenotype. Neuroimmunol 2002; 131(1-2):208-12.
22. Heggarty S, Suppiah V, Silversides J, O'doherty C, Droogan A, McDonnell G, et al. CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland. J. Neuroimmunol 2007; 187(1-2):187-91.
23. Rasmussena HB, Kellyb MA, Francisc DA, Clausena J. CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chine. J Neurol Sci 2000;184(2):143-7
24. Dyment DA, Steckley JL, Willer CJ, Armstrong H, Sadovnick AD, Risch N, et al. No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study 2002; 123(1-2):193-8.
25. van Veen T, Crusius JB, van Winsen L, Xia B, Barkhof F, Salvador Peña A, et al. CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. J Neuroimmunol 2003; 140(1-2):188-93.
26. Andreevskiǐ TV, Sudomoina MA, Gusev EI, Boǐko AN, Alekseenkov AD, Favorova OO. Polymorphism A/G in position +49 of CTLA4 exon 1 in multiple sclerosis in Russians. Mol Biol(Mosk) 2002; 3(4)6:643-8.
27. Fukazawa T, Kikuchi S, Miyagishi R, Niino M, Yabe I, Hamada T, et al. CTLA-4 gene polymorphism is not associated with conventional multiple sclerosis in Japanese. J. Neuroimmunol 2005; 159(1-2):225-9.
28. Borhani Haghighia A, Ghahramanib S, Azarpirac N, Pourjafard M, Nikseresht AR. Cytotoxic T lymphocyte associated antigen-4 exon 1 A/G polymorphism in Iranian patients with multiple sclerosis. Eur J Neurol 2008; 15(8):862-4.
29. Alizadeh M, Babron MC, Birebent B, Matsuda F, Quelvennec E, Liblau R, et al. Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. Ann Neurol 2003; 54(1):119-2.
30. Kantarci OH, Hebrink DD, Achenbach SJ, Atkinson EJ, Waliszewska A, Buckle G, et al. CTLA-4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol 2003; 134(1-2):131-41.
31. Harbo HF, Harbo EG, Celius F, Vartdal. CTLA-4 promoter and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens 1999; 53(1):106-10.
32. Suppiah V, Alloza I, Heggarty S, Goris A, Dubois B, Carton H, et al. The CTLA4 +49A/G-CT60AG haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol 2005; 164:148-53 (Pubitemid 40826773) .